|
Abstract:
|
Real world evidence and translational medicine play an important role in drug development. Propensity score methods are often used in these fields to conduct unconfounded comparisons of two populations in non-randomized data, such as comparing outcomes among populations of different drugs or diseases while making the comparison groups similar with respect to the distributions of important baseline characteristics. However, many users lack formal training on propensity scores or knowledge of best practices. Additionally, for more experienced users, propensity score analyses may be repetitive. Therefore, innovative tools are needed to streamline these analyses. In this presentation, the speaker will provide an industry perspective on the development and use of an interactive web application for performing or validating exploratory propensity score analyses. The speaker will also present on a demonstration using a case study comparing the efficacy and safety of axicabtagene ciloleucel CAR T-Cell therapy between two matched cohorts of subjects with refractory large B-cell lymphoma.
|
